Abstract
The Second Manifestations of ARTerial disease (SMART) study is a single-centre prospective cohort study among patients, newly referred to the hospital with (1) clinically manifest atherosclerotic vessel disease, or (2) marked risk factors for atherosclerosis. The first objectives of the SMART study are to determine the prevalence of concomitant arterial disease at other sites, and risk factors in patients presenting with a manifestation of arterial disease or vascular risk factor and to study the incidence of future cardiovascular events and its predictors in these high-risk patients. At least 1000 patients, aged 18 to 80 years, will undergo baseline examinations, including a questionnaire on cardiovascular disease, height, weight and blood pressure measurements, blood tests for glucose, lipids, creatinine and homocysteine, urinary tests for microproteinuria, resting twelve-lead electrocardiogram, ultrasound scanning of the abdominal aorta, kidneys and the carotid arteries, measurements of common carotid intima-media thickness and arterial stiffness, and a treadmill test to assess atherosclerosis of the leg arteries. Abnormal findings are reported to the treating specialist and general practitioner with a treatment suggestion according to current practice guidelines. Recruitment and baseline examinations began in September 1996. All cohort members will be followed for clinical cardiovascular events for a minimum of three years. In the scope of secondary prevention, the study is expected to support the design of solid based screening and treatment programmes and evidence-based cardiovascular medicine to reduce morbidity and mortality, and improve quality of life, in high-risk patients.
Similar content being viewed by others
Reference
Robinson JG, Leon AS. The prevention of cardiovascular disease. Emphasis on secondary prevention. Med Clin North Am 1994; 78: 69–98.
Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381–386.
Dormandy J, Mahir M, Ascady G, et al. Fate of the patient with chronic leg ischaemia. J Cardiovasc Surg 1989; 30: 50–57.
Norris JW. Risk of cerebral infarction, myocardial infarction and vascular death in patients with asymptomatic carotid disease, transient ischemic attack and stroke. Cerebrovasc Dis 1992; 2: 2–5.
Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12–yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434–444.
Brown JH, Hunt LP, Vites NP, Short CD, Gokal R, Mallick NP. Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant 1994; 9: 1136–1142.
EUROASPIRE Study Group. Euroaspire. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. Eur Heart J 1997; 18: 1569–1582.
Simons PCG, Graaf van der Y, Banga JD, Eikelboom BC, Algra A. Screening for asymptomatic vascular disease and risk factors in high risk patients: Assessment of current practice. Ned Tijdschr Geneeskd 1998; 142: 1096–1099.
O'Brien E, Bouchier-Hayes D, Fitzgerald D, Atkins N. The arterial organ in cardiovascular disease: ADAPT (arterial disease assessment, prevention, and treatment) clinic. Lancet 1998; 352: 1700–1702.
Kannel WB, McGee DL, Gordon T. A general cardiovascular risk profile: The Framingham Study. Am J Cardiol 1976; 38: 46–51.
The ARIC Investigators. The Atherosclerosis Risk In Communities (ARIC) Study: Design and objectives. Am J Epidemiol 1989; 129: 687–702.
Hofman A, Grobbee DE, De Jong PTVM, Van den Ouweland FA. Determinants of disease and disability in the elderly: The Rotterdam Elderly Study. Eur J Epidemiol 1991; 7: 403–422.
Fried LP, Borhani NO, Enright P, et al. for the Cardiovascular Health Study Research Group (CHS). The Cardiovascular Health Study: Design and rationale. Ann Epidemiol 1991; 1: 263–276.
van Swieten JC, Koudstaal PJ, Visser MC, Schouten JHA, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604–607.
Bamford JL, Sandercock PAG, Warlow CP, Slatterly J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1989; 20: 828.
van Leersum M, van Leeuwen MS, van der Schouw YT, Mali WP, Eikelboom BC. New duplex threshold values for angiographically determined stenosis in the internal carotid artery in the light of the NASCET an ECST [Abstract]. Cardiovasc Intervent Radiol 1995; 18: 62.
Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: Prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991; 20: 384–392.
Akkersdijk GJM, Puylaert JBCM, de Vries AC. Abdominal aortic aneurysm as an incidental finding in abdominal ultrasonography. Br J Surg 1991; 78: 1261–1263.
The Dutch TIA Trial: Protective effects of low-dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke 1988; 19: 512–517.
Revised Consensus Cholesterol. Hart Bull 1992; 23(Suppl): 9–21.
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diab Care 1997; 20: 1183–1197.
World Health Organization. Hypertension control. Report of a WHO Expert Committee. Geneva: World Health Organization, 1996.
Rose GA, Blackburn H. Cardiovascular survey methods. Geneva: World Health Organisation, 1968.
Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.
Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277: 1775–1781.
Fowkes FC. The measurement of atherosclerotic peripheral arterial disease in epidemiologic surveys. Int J Epidemiol 1988; 17: 248–254.
Taylor DC, Strandness DE Jr. Carotid artery duplex scanning. J Clin Ultrasound 1987; 15: 635–644.
Burke GL, Evans GW, Riley WA, Sharrett AR, Howard G, Barnes RW, et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 1995; 26: 386–391.
Grobbee DE, Bots ML. Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J Intern Med 1994; 236: 567–573.
Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction. The Rotterdam Study. Circulation 1997; 96: 1432–1437.
Wada T, Kodaira K, Fujishiro K, et al. Correlation of ultrasound-measured common carotid artery stiffness with pathological findings. Arterioscler Thromb 1994; 14: 479–482.
Kanters SDJM, Elgersma OEH, Banga JD, van Leeuwen MS, Algra A. Reproducibility of measurements of intima-media thickness and distensibility in the common carotid artery. Eur J Vasc Endovasc Surg 1998; 16: 28–35.
Wendelhag I, Liang Q, Gustavsson T, Wikstrand J. A new automated computerized analyzing system simplifies readings and reduces the variability in ultrasound measurement of intima-media thickness. Stroke 1997; 28: 2195–2200.
Hoeks AP, Brands PJ, Smeets FA, Reneman RS. Assessment of the distensibility of superficial arteries. Ultrasound Med Biol 1990; 16: 121–128.
Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995; 273: 1421–1428.
Brott T, Toole J. Medical compared with surgical treatment of asymptomatic carotid artery stenosis. Ann Intern Med 1995; 123: 720–722.
Barnett HJM, Meldrum HE, Eliasziw M. The dilemma of surgical treatment for patients with asymptomatic carotid disease. Ann Intern Med 1995; 123: 723–725.
Warlow C. Endarterectomy for asymptomatic carotid stenosis? Lancet 1995; 345: 1254–1255.
Nevitt MP, Ballard DJ, Hallett JW Jr. Prognosis of abdominal aortic aneurysms. A population-based study. N Engl J Med 1989; 321: 1009–1014.
Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81–106.
Kitslaar PJEHM. Consensus on diagnostics and treatment of arterial intermittent claudication. Ned Tijdschr Geneeskd 1997; 141: 2396–2400.
Golledge J. Lower-limb arterial disease. Lancet 1997; 350: 1459–1465.
Simoons ML, Casparie AF. Treatment and prevention of coronary heart disease by lowering the serum cholesterol level; Third consensus ‘Cholesterol'. Ned Tijdschr Gnkd 1998; 142: 2096–2101.
Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413–2446.
Gorgels WJMJ, van der Graaf Y, Hjemdahl P, et al. Urinary excretions of high molecular weight β-thromboglobulin and albumin are independently associated with coronary heart disease in women, a nested case-control study of middle-aged women in the Diagnostisch Onderzoek Mammacarcinoom (DOM) cohort, Utrecht, Netherlands. Am J Epidemiol 1995; 142: 1157–1164.
Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in nondiabetic subjects. Islington Diabetes Survey. Lancet 1988; 2: 530–533.
Parving HH. Microalbuminuria in essential hypertension and diabetes mellitus. J Hypertens Suppl 1996; 14: S89–S93.
Brattström l, Israelsson B, Norrving B, et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease; effects of pyridoxine and folic acid treatment. Atherosclerosis 1990; 81: 51–60.
The Stroke Prevention In Reversible Ischaemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischaemia of presumed arterial origin. Ann Neurol 1997; 42: 857–865.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Simons, P., Algra, A., van de Laak, M. et al. Second Manifestations of ARTerial disease (SMART) study: Rationale and design. Eur J Epidemiol 15, 773–781 (1999). https://doi.org/10.1023/A:1007621514757
Issue Date:
DOI: https://doi.org/10.1023/A:1007621514757